A global research-based biopharmaceutical company across immunology, oncology, neuroscience and aesthetics.
abbvie.comChairman & CEO
Robert A. Michael
CFO
Scott Reents
Founded
2013 (Abbott spin-off)
Employees
57,000+Industry
Biopharmaceuticals
Revenue (FY2025)
$61.2B
Market Cap
~$431B
Listed on
NYSE: ABBV
Headquarters
North Chicago, Illinois
Website
abbvie.comAbbVie Inc. is an American global biopharmaceutical company headquartered in North Chicago, Illinois. It was formed in 2012 as a corporate spin-off from Abbott Laboratories and became a publicly traded company in January 2013, listed on the New York Stock Exchange under the ticker ABBV. A component of the S&P 100 and S&P 500, it ranks among the largest biopharmaceutical companies in the world by revenue.
The company develops and markets medicines across immunology, oncology, neuroscience, eye care and aesthetics. Its best-known products include the immunology blockbusters Humira, Skyrizi and Rinvoq, the cancer therapies Imbruvica and Venclexta, the antipsychotic Vraylar, and - following its roughly $63 billion acquisition of Allergan in 2020 - Botox and its broader aesthetics portfolio.
AbbVie reported revenue of about US$61.2 billion for FY2025 and employs around 57,000 people worldwide. It is led by Chairman and CEO Robert A. Michael, with Scott Reents as Chief Financial Officer and Roopal Thakkar as Chief Scientific Officer. In India, AbbVie operates through the unlisted AbbVie Healthcare India Private Limited, with Bengaluru as its main hub.
Chairman & Chief Executive Officer
EVP & Chief Financial Officer
EVP, R&D & Chief Scientific Officer
Founding Chairman (2013-2025)
Interview experience
Favorable
Interview difficulty
Medium
Interview process length
About two weeks
Practice role-specific interview questions with Hyring's AI interviewer and get instant, structured feedback before the real thing.
Q: Why did you choose a career in the pharma/biotech industry?
A: Connect a genuine motivation - impact on patients, interest in science, or the pace of innovation - to your background and to AbbVie's work.
Q: In your opinion, what is the biggest development in biotechnology in the past three years?
A: Pick a real, recent advance (e.g. mRNA platforms, in-vivo cell therapies, GLP-1s or AI-driven drug discovery) and explain why it matters.
Q: How do you determine priorities when you have multiple projects due?
A: Describe a clear system: assess impact and deadlines, communicate trade-offs early, and re-plan as things change.
Q: How do you expect to make a difference at AbbVie?
A: Link your specific skills to the team's goals and show you understand where you can add value from day one.
Practice role-specific interview questions with Hyring's AI interviewer and get instant, structured feedback before the real thing.
13-20 yrs
₹41.2 L/yr - ₹51.0 L/yr
6 Salaries submitted
13-19 yrs
₹19.5 L/yr - ₹33.0 L/yr
6 Salaries submitted
3-12 yrs
₹19.0 L/yr - ₹30.0 L/yr
7 Salaries submitted
12-20 yrs
₹19.0 L/yr - ₹28.0 L/yr
20 Salaries submitted
5-12 yrs
₹17.8 L/yr - ₹29.0 L/yr
15 Salaries submitted
8-15 yrs
₹15.5 L/yr - ₹28.2 L/yr
6 Salaries submitted
Benchmark your salary against thousands of data points and discover roles that match your experience.
Create an ATS-ready resume tailored to AbbVie roles in minutes with Hyring's AI resume builder.
July 6, 2026
TEPKINLY (epcoritamab) approved by the European Commission for relapsed/refractory follicular lymphoma
The European Commission approved AbbVie's TEPKINLY (epcoritamab), in combination with lenalidomide and rituximab, for the treatment of relapsed or refractory follicular lymphoma, expanding its use in blood cancers.
#Oncology #Approval
View postJune 26, 2026
SKYRIZI becomes first IL-23 inhibitor FDA-approved for pediatric psoriatic disease
The U.S. FDA approved SKYRIZI (risankizumab-rzaa) for children six and older with moderate-to-severe plaque psoriasis or active psoriatic arthritis - the first IL-23 inhibitor approved for these pediatric patients - with a new 55 mg pre-filled syringe for weight-based dosing.
#FDA #Immunology
View postOctober 31, 2025
AbbVie reports strong third-quarter 2025 results
AbbVie reported Q3 2025 total net revenues of $15.776 billion (up 9.1%), led by Skyrizi at $4.708 billion (up 46.8%) and Rinvoq at $2.184 billion (up 35.3%), underscoring the strength of its immunology portfolio.
#Earnings #Immunology
View postSeptember 30, 2025
AbbVie begins $70 million expansion of U.S. biologics manufacturing and R&D
AbbVie broke ground on a $70 million expansion of its Worcester, Massachusetts bioresearch facility to increase biologics manufacturing capacity for oncology and immunology medicines, adding manufacturing areas plus a three-story laboratory and warehouse building.
#Manufacturing #RnD
View postJune 30, 2025
AbbVie to acquire Capstan Therapeutics to strengthen immunology pipeline
AbbVie agreed to acquire Capstan Therapeutics for up to $2.1 billion in cash, gaining CPTX2309 - an in-vivo tLNP anti-CD19 CAR-T candidate for B cell-mediated autoimmune diseases.
#Acquisition #Immunology
View postAbbVie is a global research-based biopharmaceutical company that develops and markets medicines across immunology, oncology, neuroscience, eye care and aesthetics. Its best-known products include Humira, Skyrizi, Rinvoq, Imbruvica, Venclexta and Botox.
